Abstract
Pulmonary arterial hypertension is a quite rare, but problematic disease in everyday cardiologists' practice. Prostanoids are the most important group of drugs used in this disease. One of the biggest problems encountered during treatment with analogs of prostacyclin is thrombocytopenia. Based on hematological guidelines we suggest common therapeutic schemes depending on the number of platelets or the severity of bleeding conducting the therapy.
MeSH terms
-
Animals
-
Antihypertensive Agents / adverse effects*
-
Arterial Pressure / drug effects*
-
Blood Platelets / drug effects*
-
Humans
-
Platelet Count
-
Prostaglandins I / adverse effects*
-
Pulmonary Arterial Hypertension / diagnosis
-
Pulmonary Arterial Hypertension / drug therapy*
-
Pulmonary Arterial Hypertension / physiopathology
-
Pulmonary Artery / drug effects*
-
Pulmonary Artery / physiopathology
-
Risk Factors
-
Thrombocytopenia / blood
-
Thrombocytopenia / chemically induced*
-
Treatment Outcome
Substances
-
Antihypertensive Agents
-
Prostaglandins I